上海专家团队发布早期三阴性乳腺癌治疗新方案，显著降低复发风险

Core Insights - The study led by Shanghai Jiao Tong University School of Medicine's Ruijin Hospital has established the role of platinum-based drugs in the adjuvant treatment of early-stage triple-negative breast cancer (TNBC), potentially transforming treatment protocols for this challenging subtype of breast cancer [2][5][6]. Group 1: Clinical Research Findings - The clinical research demonstrated that adding the chemotherapy drug carboplatin to the standard adjuvant chemotherapy regimen significantly reduces the postoperative recurrence risk by 34% and the mortality risk by 61% [2][6]. - The three-year disease-free survival rate post-surgery was reported at 93.1%, with a distant metastasis-free survival rate of 95.2%, and an overall survival rate of 98.3% [2][6]. - The study was presented at the San Antonio Breast Cancer Symposium and published in the Journal of Clinical Oncology, which has an impact factor of 43.4, highlighting its significance in the field [2][3]. Group 2: Study Design and Methodology - The research, initiated in 2015, involved a nationwide multicenter, prospective, randomized controlled Phase III clinical trial (RJBC1501) with 786 early-stage TNBC patients, comparing the traditional EC-T regimen with the "Ruijin regimen" that includes carboplatin [5][6]. - The study's findings fill a critical gap in the global understanding of adjuvant treatment for early-stage TNBC, providing robust clinical data that may influence future clinical practice guidelines [6]. Group 3: Historical Context and Data - The exploration of platinum-based drugs for early-stage TNBC began in 2007, when the limitations of traditional chemotherapy were recognized, leading to a decade-long research effort [5]. - Ruijin Hospital has a substantial database of over 100,000 breast cancer patients, with real-world data showing five-year survival rates of 97.5% for stage I and 91.7% for stage II TNBC patients, indicating the effectiveness of systematic treatment [6].